一个基于单变神经退行生物标志物的图形卷积网络,用于阿尔茨海默病诊断
Zongshuai Qu1, Tao Yao1, Xinghui Liu2
1School of Information and Electrical EngineeringLudong University Yantai 264025 China.
概括
这项研究引入了一种新的图形卷积网络 (GCN) 方法,使用单变神经退行生物标志物 (UNB) 来预测早期阿尔茨海默病 (AD). 带有注意模块的UNB-GCN框架在对AD患者的分类中取得了高准确性.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医学成像分析 医学成像分析
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,在早期检测方面存在挑战.
- 目前的方法很难识别微妙的,早期的AD诱导的大脑变化.
研究的目的:
- 开发一种有效的方法,用于早期预测阿尔茨海默病.
- 利用图形卷积网络 (GCN) 和新型生物标志物来改进AD检测.
主要方法:
- 提出了一个基于GCN的单变体神经退行生物标志物 (UNB) 半监督分类框架.
- 通过将个体缩模式与AD组模式进行比较,生成了UNB.
- 将注意模块集成到GCN中,以改进特征并识别受AD影响的关键大脑区域.
主要成果:
- 在阿尔茨海默病神经成像计划 (ADNI) 数据库中进行了测试.
- 在AD与认知无障碍 (CU) 分类方面取得了93.90%的准确性.
- 在AD与轻度认知障碍 (MCI) 分类方面达到82.05%的准确性.
结论:
- 对于检测AD相关的大脑皮层变化,UNB的测量优于传统的体积测量.
- 带有注意模块的UNB-GCN框架提高了早期AD检测的分类性能.
- 这种方法有助于临床医生开发干预措施来延缓AD的进展.
相关概念视频
01:26Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219